Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

GDRX vs HIMS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
GDRX
GoodRx Holdings, Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$973M
5Y Perf.-94.9%
HIMS
Hims & Hers Health, Inc.

Medical - Equipment & Services

HealthcareNYSE • US
Market Cap$6.63B
5Y Perf.+118.4%

GDRX vs HIMS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
GDRX logoGDRX
HIMS logoHIMS
IndustryMedical - Healthcare Information ServicesMedical - Equipment & Services
Market Cap$973M$6.63B
Revenue (TTM)$788M$2.35B
Net Income (TTM)$29M$128M
Gross Margin81.0%69.7%
Operating Margin12.4%4.6%
Forward P/E9.0x51.5x
Total Debt$60M$1.12B
Cash & Equiv.$262M$229M

GDRX vs HIMSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

GDRX
HIMS
StockSep 20May 26Return
GoodRx Holdings, In… (GDRX)1005.1-94.9%
Hims & Hers Health,… (HIMS)100218.4+118.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: GDRX vs HIMS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: GDRX and HIMS are tied at the top with 3 categories each — the right choice depends on your priorities. Hims & Hers Health, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
GDRX
GoodRx Holdings, Inc.
The Income Pick

GDRX has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.

  • Dividend streak 1 yrs, beta 1.58
  • Lower volatility, beta 1.58, Low D/E 9.7%, current ratio 2.61x
  • Beta 1.58, current ratio 2.61x
Best for: income & stability and sleep-well-at-night
HIMS
Hims & Hers Health, Inc.
The Growth Play

HIMS is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
  • 161.9% 10Y total return vs GDRX's -94.4%
  • 59.0% revenue growth vs GDRX's 0.6%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthHIMS logoHIMS59.0% revenue growth vs GDRX's 0.6%
ValueGDRX logoGDRXLower P/E (9.0x vs 51.5x)
Quality / MarginsHIMS logoHIMS5.5% margin vs GDRX's 3.7%
Stability / SafetyGDRX logoGDRXBeta 1.58 vs HIMS's 2.40, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)GDRX logoGDRX-25.1% vs HIMS's -51.0%
Efficiency (ROA)HIMS logoHIMS6.0% ROA vs GDRX's 1.9%, ROIC 10.7% vs 13.0%

GDRX vs HIMS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

GDRXGoodRx Holdings, Inc.
FY 2024
Prescription Transactions Revenue
84.3%$578M
Subscription Revenue
12.6%$87M
Other Revenue
3.1%$21M
HIMSHims & Hers Health, Inc.

Segment breakdown not available.

GDRX vs HIMS — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLGDRXLAGGINGHIMS

Income & Cash Flow (Last 12 Months)

GDRX leads this category, winning 4 of 6 comparable metrics.

HIMS is the larger business by revenue, generating $2.3B annually — 3.0x GDRX's $788M. Profitability is closely matched — net margins range from 5.5% (HIMS) to 3.7% (GDRX). On growth, HIMS holds the edge at +28.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricGDRX logoGDRXGoodRx Holdings, …HIMS logoHIMSHims & Hers Healt…
RevenueTrailing 12 months$788M$2.3B
EBITDAEarnings before interest/tax$184M$164M
Net IncomeAfter-tax profit$29M$128M
Free Cash FlowCash after capex$132M$73M
Gross MarginGross profit ÷ Revenue+81.0%+69.7%
Operating MarginEBIT ÷ Revenue+12.4%+4.6%
Net MarginNet income ÷ Revenue+3.7%+5.5%
FCF MarginFCF ÷ Revenue+16.7%+3.1%
Rev. Growth (YoY)Latest quarter vs prior year-4.4%+28.4%
EPS Growth (YoY)Latest quarter vs prior year-1.3%-27.3%
GDRX leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

GDRX leads this category, winning 6 of 6 comparable metrics.

At 33.3x trailing earnings, GDRX trades at a 34% valuation discount to HIMS's 50.3x P/E. On an enterprise value basis, GDRX's 4.0x EV/EBITDA is more attractive than HIMS's 42.7x.

MetricGDRX logoGDRXGoodRx Holdings, …HIMS logoHIMSHims & Hers Healt…
Market CapShares × price$973M$6.6B
Enterprise ValueMkt cap + debt − cash$771M$7.5B
Trailing P/EPrice ÷ TTM EPS33.29x50.32x
Forward P/EPrice ÷ next-FY EPS est.8.98x51.51x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple4.01x42.68x
Price / SalesMarket cap ÷ Revenue1.22x2.82x
Price / BookPrice ÷ Book value/share1.65x12.25x
Price / FCFMarket cap ÷ FCF5.92x89.61x
GDRX leads this category, winning 6 of 6 comparable metrics.

Profitability & Efficiency

GDRX leads this category, winning 5 of 8 comparable metrics.

HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $5 for GDRX. GDRX carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), GDRX scores 6/9 vs HIMS's 4/9, reflecting solid financial health.

MetricGDRX logoGDRXGoodRx Holdings, …HIMS logoHIMSHims & Hers Healt…
ROE (TTM)Return on equity+4.8%+23.7%
ROA (TTM)Return on assets+1.9%+6.0%
ROICReturn on invested capital+13.0%+10.7%
ROCEReturn on capital employed+8.8%+10.9%
Piotroski ScoreFundamental quality 0–964
Debt / EquityFinancial leverage0.10x2.07x
Net DebtTotal debt minus cash-$202M$892M
Cash & Equiv.Liquid assets$262M$229M
Total DebtShort + long-term debt$60M$1.1B
Interest CoverageEBIT ÷ Interest expense3.61x
GDRX leads this category, winning 5 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

HIMS leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $817 for GDRX. Over the past 12 months, GDRX leads with a -25.1% total return vs HIMS's -51.0%. The 3-year compound annual growth rate (CAGR) favors HIMS at 29.4% vs GDRX's -14.9% — a key indicator of consistent wealth creation.

MetricGDRX logoGDRXGoodRx Holdings, …HIMS logoHIMSHims & Hers Healt…
YTD ReturnYear-to-date+3.3%-23.2%
1-Year ReturnPast 12 months-25.1%-51.0%
3-Year ReturnCumulative with dividends-38.4%+116.6%
5-Year ReturnCumulative with dividends-91.8%+137.6%
10-Year ReturnCumulative with dividends-94.4%+161.9%
CAGR (3Y)Annualised 3-year return-14.9%+29.4%
HIMS leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

GDRX leads this category, winning 2 of 2 comparable metrics.

GDRX is the less volatile stock with a 1.58 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GDRX currently trades 48.9% from its 52-week high vs HIMS's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricGDRX logoGDRXGoodRx Holdings, …HIMS logoHIMSHims & Hers Healt…
Beta (5Y)Sensitivity to S&P 5001.58x2.40x
52-Week HighHighest price in past year$5.81$70.43
52-Week LowLowest price in past year$1.77$13.74
% of 52W HighCurrent price vs 52-week peak+48.9%+36.4%
RSI (14)Momentum oscillator 0–10066.154.5
Avg Volume (50D)Average daily shares traded2.3M34.9M
GDRX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates GDRX as "Hold" and HIMS as "Hold". Consensus price targets imply 15.6% upside for HIMS (target: $30) vs 12.3% for GDRX (target: $3).

MetricGDRX logoGDRXGoodRx Holdings, …HIMS logoHIMSHims & Hers Healt…
Analyst RatingConsensus buy/hold/sellHoldHold
Price TargetConsensus 12-month target$3.19$29.67
# AnalystsCovering analysts2419
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+21.3%+1.4%
Insufficient data to determine a leader in this category.
Key Takeaway

GDRX leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). HIMS leads in 1 (Total Returns).

Best OverallGoodRx Holdings, Inc. (GDRX)Leads 4 of 6 categories
Loading custom metrics...

GDRX vs HIMS: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is GDRX or HIMS a better buy right now?

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus 0. 6% for GoodRx Holdings, Inc. (GDRX). GoodRx Holdings, Inc. (GDRX) offers the better valuation at 33. 3x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate GoodRx Holdings, Inc. (GDRX) a "Hold" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — GDRX or HIMS?

On trailing P/E, GoodRx Holdings, Inc.

(GDRX) is the cheapest at 33. 3x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, GoodRx Holdings, Inc. is actually cheaper at 9. 0x.

03

Which is the better long-term investment — GDRX or HIMS?

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -91. 8% for GoodRx Holdings, Inc. (GDRX). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus GDRX's -94. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — GDRX or HIMS?

By beta (market sensitivity over 5 years), GoodRx Holdings, Inc.

(GDRX) is the lower-risk stock at 1. 58β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 52% more volatile than GDRX relative to the S&P 500. On balance sheet safety, GoodRx Holdings, Inc. (GDRX) carries a lower debt/equity ratio of 10% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — GDRX or HIMS?

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus 0. 6% for GoodRx Holdings, Inc. (GDRX). On earnings-per-share growth, the picture is similar: GoodRx Holdings, Inc. grew EPS 104. 1% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — GDRX or HIMS?

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus 3. 8% for GoodRx Holdings, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GDRX leads at 13. 4% versus 5. 2% for HIMS. At the gross margin level — before operating expenses — GDRX leads at 82. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is GDRX or HIMS more undervalued right now?

On forward earnings alone, GoodRx Holdings, Inc.

(GDRX) trades at 9. 0x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 42. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HIMS: 15. 6% to $29. 67.

08

Which pays a better dividend — GDRX or HIMS?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is GDRX or HIMS better for a retirement portfolio?

For long-horizon retirement investors, GoodRx Holdings, Inc.

(GDRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GDRX: -94. 4%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between GDRX and HIMS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GDRX is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

GDRX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 48%
Run This Screen
Stocks Like

HIMS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform GDRX and HIMS on the metrics below

Revenue Growth>
%
(GDRX: -4.4% · HIMS: 28.4%)
Net Margin>
%
(GDRX: 3.7% · HIMS: 5.5%)
P/E Ratio<
x
(GDRX: 33.3x · HIMS: 50.3x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.